Emerging drugs for the treatment of adrenocortical carcinoma

References

• Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006 May;30(5):872–878.
   PubMed Web of Science ®Google Scholar
• Datta J, Roses RE. Surgical management of adrenocortical carcinoma: an evidence-based approach. Surg Oncol Clin N Am. 2016 Jan;25(1):153–170.
   PubMed Web of Science ®Google Scholar
• Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer. 1993 Dec 1;72(11):3145–3155.
   PubMed Web of Science ®Google Scholar
• Assie G, Letouze E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014 Jun;46(6):607–612.
   PubMed Web of Science ®Google Scholar
• Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016 May 9;29(5):723–736.
   PubMed Web of Science ®Google Scholar
• Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J clin oncol. 2010;28(23):e401–e402.
   PubMed Web of Science ®Google Scholar
• Kerkhofs TMA, Ettaieb MHT, Hermsen IGC, et al. Developing treatment for adrenocortical carcinoma. Endocr Relat Cancer. 2015;22(6):R325.
   PubMed Web of Science ®Google Scholar
• Libe R, Borget I, Ronchi CL, et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European network for the study of adrenal tumor (ENSAT) study. Ann Oncol. 2015 Oct;26(10):2119–2125.
   PubMed Web of Science ®Google Scholar
• Long SE, Miller BS. Adrenocortical cancer treatment. Surg Clin North Am. 2019 Aug;99(4):759–771.
   PubMed Web of Science ®Google Scholar
• Megerle F, Kroiss M, Hahner S, et al. Advanced adrenocortical carcinoma - What to do when first-line therapy fails? Exp Clin Endocrinol Diabetes: Official journal, German Society of Endocrinology [and] German Diabetes Association. 2019 Feb;127(2–03):109–116.
   PubMed Web of Science ®Google Scholar
• Hescot S, Slama A, Lombes A, et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer. 2013 Jun;20(3):371–381.
   PubMed Web of Science ®Google Scholar
• Sbiera S, Leich E, Liebisch G, et al. Mitotane inhibits Sterol-O-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 2015 Nov;156(11):3895–3908.
   PubMed Web of Science ®Google Scholar
• Megerle F, Herrmann W, Schloetelburg W, et al. Mitotane monotherapy in patients with advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1686–1695.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189–2197.
   PubMed Web of Science ®Google Scholar
• Haak HR, Hermans J, Van De Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994;69(5):947–951.
   PubMed Web of Science ®Google Scholar
• Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010 Jun;17(2):445–453.
   PubMed Web of Science ®Google Scholar
• Pinto EM, Chen X, Easton J, et al. Genomic landscape of paediatric adrenocortical tumours. Nat Commun. 2015 Mar 6;6(1):6302.
   PubMedGoogle Scholar
• Lehmann T, Wrzesinski T. The molecular basis of adrenocortical cancer. Cancer Genet. 2012 Apr;205(4):131–137.
   PubMed Web of Science ®Google Scholar
• Giordano TJ, Thomas DG, Kuick R, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol. 2003 Feb;162(2):521–531.
   PubMed Web of Science ®Google Scholar
• De Martino MC, Van Koetsveld PM, Feelders RA, et al. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. Endocrine. 2019 Jun;64(3):673–684.
   PubMed Web of Science ®Google Scholar
• Weigel B, Malempati S, Reid JM, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the children’s oncology group. Pediatr Blood Cancer. 2014;61(3):452–456.
   PubMed Web of Science ®Google Scholar
• Lerario AM, Worden FP, Ramm CA, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Horm Cancer. 2014 Aug;5(4):232–239.
   PubMed Web of Science ®Google Scholar
• Naing A, Lorusso P, Fu S, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013 Mar 5;108(4):826–830.
   PubMed Web of Science ®Google Scholar
• Haluska P, Worden F, Olmos D, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol. 2010 Mar;65(4):765–773.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Berruti A, Baudin E, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426–435.
   PubMed Web of Science ®Google Scholar
• Xu YZ, Zhu Y, Shen ZJ, et al. Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine. 2011 Dec;40(3):445–451.
   PubMed Web of Science ®Google Scholar
• Wortmann S, Quinkler M, Ritter C, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010 Feb;162(2):349–356.
   PubMed Web of Science ®Google Scholar
• Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012 Mar;166(3):451–458.
   PubMed Web of Science ®Google Scholar
• Kroiss M, Quinkler M, Johanssen S, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012 Oct;97(10):3495–3503.
   PubMed Web of Science ®Google Scholar
• O’Sullivan C, Edgerly M, Velarde M, et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014;99(4):1291–1297.
   PubMed Web of Science ®Google Scholar
• Saucier C, Khoury H, Lai KM, et al. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2345–2350.
   PubMed Web of Science ®Google Scholar
• Phan LM, Fuentes-Mattei E, Wu W, et al. Hepatocyte growth factor/cMET pathway activation enhances cancer hallmarks in adrenocortical carcinoma. Cancer Res. 2015 Oct 1;75(19):4131–4142.
   PubMed Web of Science ®Google Scholar
• Kroiss M, Megerle F, Kurlbaum M, et al. Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib. J Clin Endocrinol Metab. 2020;105(5):1461–1468.
   Web of Science ®Google Scholar
• De Martino MC, Al Ghuzlan A, Aubert S, et al. Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. J Clin Endocrinol Metab. 2013 Oct;98(10):4080–4088.
   PubMed Web of Science ®Google Scholar
• Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res. 2009 Jan 15;15(2):668–676.
   PubMed Web of Science ®Google Scholar
• García-Donas J, Polo SH, Guix M, et al. Phase II study of dovitinib in first line metastatic or (non resectable primary) adrenocortical carcinoma (ACC): SOGUG study 2011-03. J clin oncol. 2014;32(15_suppl):4588.
   Web of Science ®Google Scholar
• Miller KC, Chintakuntlawar AV, Hilger C, et al. Salvage therapy with multikinase inhibitors and immunotherapy in advanced adrenal cortical carcinoma. J Endocr Soc. 2020;4(7):bvaa069–bvaa069.
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, El-Rayes BF, Tolcher AW, et al. A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br J Cancer. 2017 Nov 21;117(11):1592–1599.
   PubMed Web of Science ®Google Scholar
• Adam P, Hahner S, Hartmann M, et al. Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome. Mod Pathol. 2010 Dec;23(12):1596–1604.
   PubMed Web of Science ®Google Scholar
• Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008 Jun;93(6):2057–2062.
   PubMed Web of Science ®Google Scholar
• Samnotra V, Vassilopoulou-Sellin R, Fojo AT, et al. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J clin oncol. 2007;25(18_suppl):15527.
   Web of Science ®Google Scholar
• Zhang Y, Wang X. Targeting the Wnt/beta-catenin signaling pathway in cancer. J Hematol Oncol. 2020 Dec 4;13(1):165.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Bao R, Sweis RF, et al. WNT/beta-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 2019 May 15;25(10):3074–3083.
   PubMed Web of Science ®Google Scholar
• Basham KJ, Rodriguez S, Turcu AF, et al. A ZNRF3-dependent Wnt/β-catenin signaling gradient is required for adrenal homeostasis. Genes Dev. 2019 Feb 1;33(3–4):209–220.
   PubMed Web of Science ®Google Scholar
• Janku F, De Vos F, De Miguel M, et al. Abstract CT034: Phase I study of WNT974 + spartalizumab in patients (pts) with advanced solid tumors. Cancer Res. 2020;80(16Supplement):CT034–CT034.
   Google Scholar
• Klempner SJ, Bendell JC, Villaflor VM, et al. DKN-01 in combination with pembrolizumab in patients with advanced gastroesophageal adenocarcinoma (GEA): tumoral DKK1 expression as a predictor of response and survival. J clin oncol. 2020;38(4_suppl):357.
   Web of Science ®Google Scholar
• Zhu G, Song J, Chen W, et al. Expression and role of Dickkopf-1 (Dkk1) in tumors: from the cells to the patients. Cancer Manag Res. 2021;13:659–675.
   PubMed Web of Science ®Google Scholar
• Dotan E, Cardin DB, Lenz H-J, et al. Phase Ib study of Wnt inhibitor ipafricept with gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic cancer. Clin Cancer Res. 2020;26(20):5348–5357.
   PubMed Web of Science ®Google Scholar
• Moore KN, Gunderson CC, Sabbatini P, et al. A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2019 Aug 1;154(2):294–301.
   PubMed Web of Science ®Google Scholar
• Diamond JR, Becerra C, Richards D, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184(1):53–62.
   PubMed Web of Science ®Google Scholar
• OncoTherapy Science [Press Release]. [cited 2021 Apr 25]. Available from: oncotherapycojp/en/research-development/drug-discovery-research/otsa101/.
   Google Scholar
• Sachdev JC, Maitland ML, Sharma M, et al. PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: results of a phase I dose escalation and expansion study. J clin oncol. 2018;36(15_suppl):5565.
   Web of Science ®Google Scholar
• Lippert J, Appenzeller S, Liang R, et al. Targeted molecular analysis in adrenocortical carcinomas: a strategy toward improved personalized prognostication. J Clin Endocrinol Metab. 2018 Dec 1;103(12):4511–4523.
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Sbiera S, Altieri B, et al. Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocr Relat Cancer. 2015;22(4):531–543.
   PubMed Web of Science ®Google Scholar
• Simon DP, Giordano TJ, Hammer GD. Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma. Clin Cancer Res. 2012;18(9):2452–2464.
   PubMed Web of Science ®Google Scholar
• Cook N, Basu B, Smith D-M, et al. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer. 2018 Mar 1;118(6):793–801.
   PubMed Web of Science ®Google Scholar
• Crona J, Beuschlein F. Adrenocortical carcinoma — towards genomics guided clinical care. Nat Rev Endocrinol. 2019 Sep 1;15(9):548–560.
   PubMed Web of Science ®Google Scholar
• Hadjadj D, Kim S-J, Denecker T, et al. A hypothesis-driven approach identifies CDK4 and CDK6 inhibitors as candidate drugs for treatments of adrenocortical carcinomas. Aging (Albany NY). 2017;9(12):2695–2716.
   PubMedGoogle Scholar
• Liang R, Weigand I, Lippert J, et al. Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma. Front Endocrinol (Lausanne). 2020;11:219.
   PubMed Web of Science ®Google Scholar
• Fiorentini C, Fragni M, Tiberio GAM, et al. Palbociclib inhibits proliferation of human adrenocortical tumor cells. Endocrine. 2018 Jan 1;59(1):213–217.
   PubMed Web of Science ®Google Scholar
• Nilubol N, Boufraqech M, Zhang L, et al. Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response. Oncotarget. 2018;9(68):33030–33042.
   Google Scholar
• Pereira SS, Monteiro MP, Costa MM, et al. MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors. J Cell Biochem. 2019;120(1):894–906.
   PubMed Web of Science ®Google Scholar
• Bussey KJ, Bapat A, Linnehan C, et al. Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. Clin Transl Med. 2016 Mar;5(1):1.
   PubMedGoogle Scholar
• Hui W, Liu S, Zheng J, et al. Nutlin-3a as a novel anticancer agent for adrenocortical carcinoma with CTNNB1 mutation. Cancer Med. 2018;7(4):1440–1449.
   PubMed Web of Science ®Google Scholar
• Paré L, Pascual T, Seguí E, et al. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol. 2018 Oct 1;29(10):2121–2128.
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018 Apr 17;48(4):812–830.e14.
   PubMed Web of Science ®Google Scholar
• Landwehr L-S, Altieri B, Schreiner J, et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer. 2020;8(1):e000469.
   PubMed Web of Science ®Google Scholar
• Fay AP, Signoretti S, Callea M, et al. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015;3(1):3.
   PubMedGoogle Scholar
• Tierney JF, Vogle A, Poirier J, et al. Expression of programmed death ligand 1 and 2 in adrenocortical cancer tissues: an exploratory study. Surgery. 2019 Jan;165(1):196–201.
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017. doi:10.1200/PO.17.00073.
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery S, Keegan P, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019 Feb 20;25(13):3753–3758. clincanres.4070.2018.
   Web of Science ®Google Scholar
• Lang J, Capasso A, Jordan KR, et al. Development of an adrenocortical cancer humanized mouse model to characterize Anti-PD1 effects on tumor microenvironment. J Clin Endocrinol Metab. 2020 Jan 1;105(1):26–42.
   Web of Science ®Google Scholar
• Le Tourneau C, Hoimes C, Zarwan C, et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2018 Oct 22;6(1):111.
   PubMed Web of Science ®Google Scholar
• Carneiro BA, Konda B, Costa RB, et al. Nivolumab in metastatic adrenocortical carcinoma: results of a Phase 2 trial. J Clin Endocrinol Metab. 2019 Dec 1;104(12):6193–6200.
   PubMed Web of Science ®Google Scholar
• Campbell MT, Xie W, Shah AY, et al. 986P - Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours. Ann Oncol. 2019 Oct 1;30:v400.
   Google Scholar
• Habra MA, Stephen B, Campbell M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 Sep 18;7(1):253.
   PubMed Web of Science ®Google Scholar
• Raj N, Zheng Y, Kelly V, et al. PD-1 blockade in advanced adrenocortical carcinoma. Journal of Clinical Oncology. 2020 Jan 1;38(1):71–80.
   PubMed Web of Science ®Google Scholar
• Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020 Jan 1;21(1):121–133.
   PubMed Web of Science ®Google Scholar
• Bedrose S, Miller KC, Altameemi L, et al. Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. J Immunother Cancer. 2020 Jul;8(2):e001009.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Kerppola RE, Kerppola TK. ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo. Endocr Relat Cancer. 2016 Apr;23(4):1–19.
   PubMed Web of Science ®Google Scholar
• Smith DC, Kroiss M, Kebebew E, et al. A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Invest New Drugs. 2020 Oct;38(5):1421–1429.
   PubMed Web of Science ®Google Scholar
• Figueiredo BC, Cavalli LR, Pianovski MA, et al. Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J Clin Endocrinol Metab. 2005 Feb;90(2):615–619.
   PubMed Web of Science ®Google Scholar
• Doghman M, Karpova T, Rodrigues GA, et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol. 2007 Dec;21(12):2968–2987.
   PubMedGoogle Scholar
• Doghman M, Cazareth J, Douguet D, et al. Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists. J Clin Endocrinol Metab. 2009 Jun;94(6):2178–2183.
   PubMed Web of Science ®Google Scholar
• Orphagen Pharmaceuticals. [cited 2021 Apr 25]. Available from: http://www.orphagen.com/pipeline/
   Google Scholar
• Munster PN, Sachdev JC, Fleming GF, et al. Relacorilant (RELA) with nab-paclitaxel (NP): safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA). J clin oncol. 2019;37(15_suppl):4130.
   Web of Science ®Google Scholar
• Hahner S, Kreissl MC, Fassnacht M, et al. [131I]iodometomidate for targeted radionuclide therapy of advanced adrenocortical carcinoma. J Clin Endocrinol Metab. 2012 Mar;97(3):914–922.
   PubMed Web of Science ®Google Scholar
• Grisanti S, Filice A, Basile V, et al. Treatment with 90Y/177Lu-DOTATOC in patients with metastatic adrenocortical carcinoma expressing somatostatin receptors. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e1–e5.
   Web of Science ®Google Scholar
• Van Erp NP, Guchelaar HJ, Ploeger BA, et al. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol. 2011 Apr;164(4):621–626.
   PubMed Web of Science ®Google Scholar
• De Reynies A, Assie G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol. 2009 Mar 1;27(7):1108–1115.
   PubMed Web of Science ®Google Scholar
• Mohan DR, Lerario AM, Else T, et al. Targeted assessment of G0S2 methylation identifies a rapidly recurrent, routinely fatal molecular subtype of adrenocortical carcinoma. Clin Cancer Res. 2019 Jun 1;25(11):3276–3288.
   PubMed Web of Science ®Google Scholar